Status:
COMPLETED
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia, Postherpetic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the safety of the long-term use of pregabalin.
Eligibility Criteria
Inclusion
- Patients who completed the 13-week treatment of postherpetic neuralgia in Study A0081120.
- Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study.
Exclusion
- Patients who experienced serious adverse events in the preceding study (A0081120) that were determined by the investigator or the study sponsor to be causally related to the study medication.
- Patients exhibiting treatment non-compliance in the preceding study (A0081120)
Key Trial Info
Start Date :
January 12 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2008
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT00424372
Start Date
January 12 2007
End Date
August 19 2008
Last Update
August 27 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan, 460-0001
2
Kobayashi Clinic
Urayasu, Chiba, Japan, 279-0012
3
Okabe Hospital
Kasuya-gun, Fukuoka, Japan, 811-2122
4
Gunma Pain Clinic Hospital
Maebashi, Gunma, Japan, 379-2147